Adolescent @entity1 with @entity5 reside in a "no- @entity1 's land" between the world of pediatric oncology and that of "adult" medical oncology. As compared to younger and older @entity1 , adolescents and young adults are under-represented on clinical trials. This relative lack of participation in clinical protocols has been associated to a lack of progress in survival improvement over the last years. One of the main reasons for the deficit in protocol enrolment and the worse outcome of adolescents (when compared in particular to @entity1 ) is the lack of awareness by the public, community and healthcare systems that @entity5 may occur in this age group. However, physicians--inadequately trained or reluctant to care for adolescents--have important responsibilities. Most 15- to 19-year-olds diagnosed with @entity5 are treated at adult facilities, although two-thirds to three-fourths of their @entity5 are typical of those that occur in the pediatric age range. The best choice may be to treat them according to their type of @entity5 , not according to their age: "pediatric" @entity5 treated by pediatric oncologists, "adult" @entity5 by adult medical oncologists, regardless of the @entity1 's age. This solution, however, is probably appropriate for the @entity5 , but not necessarily for the @entity1 . Adolescents are neither old @entity1 nor young adults, and are very complicated individuals, with unique socio-psychological problems and needs, that may be addressed only by dedicated professionals, adequately trained and supported. The ultimate challenge is the development of a new discipline, adolescent/teenage and young adult oncology, devoted to the care of these @entity1 .

Participation of adolescents with XXXX in clinical trials.

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient', 'man'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'cancer', 'tumors']
@entity5 :: (MESH:D009369,Disease) :: ['cancer']
